Shares of Gilead Sciences Inc. GILD rallied 1.52% to $92.38 Wednesday, on what proved to be an all-around great trading ...

(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention ...

Biotech dealmaking is back — but smaller and more intimate. Deals disclosed in the early days of the new year indicate that ...

Shares of Gilead Sciences Inc. GILD inched 0.07% higher to $89.94 Monday, on what proved to be an all-around positive trading ...

Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

In the latest trading session, Gilead Sciences (GILD) closed at $92.38, marking a +1.52% move from the previous day.

Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91 which represents a slight increase of $1.06 or 1.18% from the prior close of $89.94. The stock opened at $90.59 and touched ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...